HHS Secretary Robert F. Kennedy Jr. faced hours of congressional grilling on Wednesday over his proposed budget cuts and ...

Sanofi announced plans to invest “at least” $20 billion in the US through 2030, following similar commitments made by several ...

Plus, news about Allogene, Kyverna, Sernova, ADC Therapeutics, Acelyrin, Alumis, Atara, Lava Therapeutics and Repare Therapeutics ...

AbbVie partners with ADARx Pharmaceuticals in $335M upfront deal for siRNA tech collaboration across neuroscience, immunology ...

GSK to pay $1.2B upfront to Boston Pharmaceuticals for efimosfermin alfa, a MASH drug candidate. Deal includes $800M in ...

Novo Nordisk is partnering with Septerna in a $2B+ deal to develop oral small molecules for obesity and diabetes, focusing on ...

Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...

An order from a federal appeals court has kicked the battle wide open again over who holds the key patents for CRISPR-Cas9, a ...

A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential ...

The Trump administration laid out for the first time how Part B drugs could be selected for Medicare drug price negotiations ...

Cytokinetics's aficamten outperforms metoprolol in Phase 3 heart disease trial, but FDA approval delayed to December due to ...

Plus, news about Neumora, Erasca, FibroGen, Tilt Biotherapeutics, Sangamo, Leap Therapeutics, Remedy Plan, Lexeo, Karyopharm, Tango Therapeutics and Humacyte.